{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:14:38Z","timestamp":1790363678543,"version":"4.1.0"},"reference-count":221,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"South African National Research Foundation (SA NRF)","award":["UID 129135"],"award-info":[{"award-number":["UID 129135"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Although chemotherapeutic treatment regimens are currently available, and considerable effort has been lavished on the development of new drugs for the treatment of tuberculosis (TB), the disease remains deeply intractable and widespread. This is due not only to the nature of the life cycle and extraordinarily disseminated habitat of the causative pathogen, principally Mycobacterium tuberculosis (Mtb), in humans and the multi-drug resistance of Mtb to current drugs, but especially also to the difficulty of enabling universal treatment of individuals, immunocompromised or otherwise, in widely differing socio-economic environments. For the purpose of globally eliminating TB by 2035, the World Health Organization (WHO) introduced the \u201cEnd-TB\u201d initiative by employing interventions focusing on high impact, integrated and patient-centered approaches, such as individualized therapy. However, the extraordinary shortfall in stipulated aims, for example in actual treatment and in TB preventative treatments during the period 2018\u20132022, latterly and greatly exacerbated by the COVID-19 pandemic, means that even greater pressure is now placed on enhancing our scientific understanding of the disease, repurposing or repositioning old drugs and developing new drugs as well as evolving innovative treatment methods. In the specific context of multidrug resistant Mtb, it is furthermore noted that the incidence of extra-pulmonary TB (EPTB) has significantly increased. This review focusses on the potential of utilizing self-double-emulsifying drug delivery systems (SDEDDSs) as topical drug delivery systems for the dermal route of administration to aid in treatment of cutaneous TB (CTB) and other mycobacterial infections as a prelude to evaluating related systems for more effective treatment of CTB and other mycobacterial infections at large. As a starting point, we consider here the possibility of adapting the highly lipophilic riminophenazine clofazimine, with its potential for treatment of multi-drug resistant TB, for this purpose. Additionally, recently reported synergism achieved by adding clofazimine to first-line TB regimens signifies the need to consider clofazimine. Thus, the biological effects and pharmacology of clofazimine are reviewed. The potential of plant-based oils acting as emulsifiers, skin penetration enhancers as well as these materials behaving as anti-microbial components for transporting the incorporated drug are also discussed.<\/jats:p>","DOI":"10.3390\/antibiotics11060806","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T22:17:01Z","timestamp":1655331421000},"page":"806","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems"],"prefix":"10.3390","volume":"11","author":[{"given":"Dani\u00e9lle","family":"van Staden","sequence":"first","affiliation":[{"name":"Centre of Excellence for Pharmaceutical Sciences (Pharmacen\u2122), Building G16, Faculty of Health Sciences, North-West University, Potchefstroom 2520, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8554-1823","authenticated-orcid":false,"given":"Richard K.","family":"Haynes","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Pharmaceutical Sciences (Pharmacen\u2122), Building G16, Faculty of Health Sciences, North-West University, Potchefstroom 2520, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2489-1616","authenticated-orcid":false,"given":"Joe M.","family":"Viljoen","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Pharmaceutical Sciences (Pharmacen\u2122), Building G16, Faculty of Health Sciences, North-West University, Potchefstroom 2520, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.semnuclmed.2017.10.005","article-title":"Tuberculosis","volume":"48","author":"Ankrah","year":"2018","journal-title":"Semin. Nucl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijid.2016.10.021","article-title":"Applicability of the shorter \u2018Bangladesh regimen\u2019 in high multidrug-resistant tuberculosis settings","volume":"56","author":"Sotgiu","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_3","first-page":"CD012918","article-title":"Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis","volume":"1","author":"Grace","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1473-3099(18)30219-6","article-title":"Antimicrobial resistance among migrants in Europe: A systematic review and meta-analysis","volume":"18","author":"Nellums","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1473-3099(18)30004-5","article-title":"A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: A molecular epidemiological study","volume":"18","author":"Walker","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.11604\/pamj.2017.27.102.11577","article-title":"Cutaneous tuberculosis in Bamako, Mali","volume":"27","author":"Dicko","year":"2017","journal-title":"Pan. Afr. Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100143","DOI":"10.1016\/j.jctube.2020.100143","article-title":"Migration and tuberculosis in Europe","volume":"18","author":"Boudville","year":"2020","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.5588\/ijtld.17.0629","article-title":"Impact of quality improvement in tuberculosis laboratories in low-and lower-middle-income countries: A systematic review","volume":"22","author":"Olaru","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201803-0497ED","article-title":"Drug-Resistant Tuberculosis in Europe. What Are We Waiting For?","volume":"198","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3201\/eid2503.181003","article-title":"Cross-border movement of highly drug-resistant mycobacterium tuberculosis from Papua New Guinea to Australia through Torres Strait Protected Zone, 2010\u20132015","volume":"25","author":"Bainomugisa","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_11","first-page":"E217","article-title":"Tuberculosis notifications in Australia, 2012 and 2013","volume":"39","author":"Toms","year":"2015","journal-title":"Commun. Dis. Intell. Q. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"624","DOI":"10.5588\/ijtld.16.0845","article-title":"Tuberculosis in migrants in low-incidence countries: Epidemiology and intervention entry points","volume":"21","author":"Mor","year":"2017","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/cid\/cix561","article-title":"Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993\u20132014","volume":"65","author":"Smith","year":"2017","journal-title":"Clin. Infect. Dis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijid.2016.12.015","article-title":"Improving access to tuberculosis preventive therapy and treatment for children","volume":"56","author":"Marais","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1016\/S2214-109X(17)30289-9","article-title":"The global burden of tuberculosis mortality in children: A mathematical modelling study","volume":"5","author":"Dodd","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(14)60420-7","article-title":"Black RE. Importance of tuberculosis control to address child survival","volume":"383","author":"Graham","year":"2014","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1473-3099(18)30648-0","article-title":"Public health burden of antimicrobial resistance in Europe","volume":"19","author":"Tacconelli","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1073\/pnas.1717160115","article-title":"Technologies to address antimicrobial resistance","volume":"115","author":"Baker","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","unstructured":"World Health Organization (WHO) (2022, March 18). The End TB Strategy. Available online: http:\/\/www.who.int\/tb\/post2015_TBstrategy.pdf?ua=1."},{"key":"ref_20","unstructured":"World Health Organization (WHO) (2021, April 10). UN General Assembly High-Level Meeting on the Fight Against Tuberculosis. Available online: https:\/\/www.who.int\/news-room\/events\/un-general-assembly-high-level-meeting-on-ending-tb."},{"key":"ref_21","unstructured":"(2021, May 20). Stop TB Partnership. Available online: http:\/\/www.stoptb.org\/global\/advocacy\/unhlm_whatis.asp."},{"key":"ref_22","unstructured":"General Assembly of the United Nations (2022, March 20). United Nations High-Level Meeting on the Fight to End Tuberculosis 26 September 2018, UNHQ, New York. Available online: https:\/\/www.un.org\/pga\/73\/event\/fight-to-end-tuberculosis\/."},{"key":"ref_23","unstructured":"United Nations: Meetings Coverage and Press Releases (2021, May 20). World Leaders Reaffirm Commitment to End Tuberculosis by 2030, as General Assembly Adopts Declaration Outlining Actions for Increased Financing, Treatment Access. Available online: https:\/\/www.un.org\/press\/en\/2018\/ga12067.doc.htm."},{"key":"ref_24","unstructured":"World Health Organization (WHO) (2021). Global Tuberculosis Report 2021, World Health Organization (WHO). (Electronic Version)."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cmi.2018.11.010","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis","volume":"25","author":"Lange","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12249-018-1251-5","article-title":"Topical delivery of artemisone, clofazimine and decoquinate encapsulated in vesicles and their in vitro efficacy against Mycobacterium tuberculosis","volume":"20","author":"Viljoen","year":"2019","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imig.12275","article-title":"Latent Tuberculosis Infection Screening Acceptability among Migrant Farmworkers","volume":"55","author":"Osuchukwu","year":"2017","journal-title":"Int. Migr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eimc.2017.10.015","article-title":"Pathogenesis of tuberculosis and other mycobacteriosis","volume":"36","author":"Cardona","year":"2018","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijid.2016.11.416","article-title":"Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?","volume":"56","author":"Centis","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1590\/abd1806-4841.20142334","article-title":"Cutaneous tuberculosis: Epidemiologic, etiopathogenic and clinical aspects-part I","volume":"89","author":"Figueiredo","year":"2014","journal-title":"An. Bras. Dermatol."},{"key":"ref_31","unstructured":"Churchyard, G. (2022, February 19). This Kills More South Africans Than Any Other Disease. There\u2019s a New Way to Stop it. BHEKISISA Centre for Health Journalism. Available online: https:\/\/bhekisisa.org\/article\/2019-03-28-00-3hp-latent-tb-treatment-short-course-guidelines-regimen-isoniazid-rifapentine."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.tube.2014.12.006","article-title":"Cutaneous tuberculosis overview and current treatment regimens","volume":"95","author":"Viljoen","year":"2015","journal-title":"Tuberculosis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1056\/NEJMcpc1810390","article-title":"Case 2-2019: A 36-year-old man with rash, abdominal pain, and lymphadenopathy","volume":"380","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/0975-2870.122776","article-title":"Cutaneous tuberculosis, tuberculosis verrucosa cutis","volume":"7","author":"Mohanty","year":"2014","journal-title":"Med. J. Dr. D. Y. Patil. Univ."},{"key":"ref_35","unstructured":"World Health Organization (WHO) (2018). Global Tuberculosis Report 2018, World Health Organization (WHO)."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.envint.2019.01.013","article-title":"Ambient air pollution exposures and risk of drug-resistant tuberculosis","volume":"124","author":"Yao","year":"2019","journal-title":"Environ. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4103\/jfmpc.jfmpc_99_17","article-title":"Epidemiological profile of multidrug-resistant tuberculosis patients in Gorakhpur Division, Uttar Pradesh, India","volume":"7","author":"Venkatesh","year":"2018","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jgar.2017.10.006","article-title":"Drug-resistant Mycobacterium tuberculosis: Epidemiology and role of morphological alterations","volume":"12","author":"Velayati","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijid.2017.01.031","article-title":"The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains","volume":"56","author":"McBryde","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1469-0691.2004.00758.x","article-title":"Tuberculosis in HIV-infected patients: A comprehensive review","volume":"10","author":"Aaron","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.aller.2018.06.005","article-title":"Evaluation of interleukin-12 receptor \u03b21 and interferon gamma receptor 1 deficiency in patients with disseminated BCG infection","volume":"47","author":"Pourakbari","year":"2019","journal-title":"Allergol. Immunopathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.arbres.2017.02.006","article-title":"Diagnosis and treatment of drug-resistant tuberculosis","volume":"53","author":"Caminero","year":"2017","journal-title":"Arch. Bronconeumol."},{"key":"ref_43","unstructured":"(2022, February 15). Tuberculosis (TB). Division of Tuberculosis Elimination. Centers for Disease Control and Prevention. CDC Twenty Four Seven. Saving Lives, Protecting People, Available online: https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/drtb\/mdrtb.htm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1155\/2007\/986794","article-title":"The emergence of extensively drug-resistant tuberculosis (TB): TB\/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada","volume":"18","author":"Alexander","year":"2007","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1567-1348(03)00086-8","article-title":"Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: A case-control study","volume":"3","author":"Sharma","year":"2003","journal-title":"Infect. Genet. Evol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1086\/516146","article-title":"Rifampin monoresistant tuberculosis in New York City, 1993\u20131994","volume":"25","author":"Munsiff","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.biopha.2018.04.176","article-title":"Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promis-es on the horizon","volume":"103","author":"Bhat","year":"2018","journal-title":"Biomed Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.rppnen.2017.10.009","article-title":"New drugs and perspectives for new anti-tuberculosis regimens","volume":"24","author":"Tiberi","year":"2018","journal-title":"Pulmonology"},{"key":"ref_49","first-page":"52.e1","article-title":"Tuberculosis treatment for children: An update","volume":"88","author":"Amador","year":"2018","journal-title":"An. de Pediatr\u00eda"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/jac\/dkx150","article-title":"Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?","volume":"72","author":"Maitre","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Tiberi, S., Utjesanovic, N., Galvin, J., Centis, R., D\u2019Ambrosio, L., van den Boom, M., Zumla, A., and Migliori, G.B. (2022). Drug resistant TB\u2013latest developments in epidemiology, diagnostics and management. IJID, (in press).","DOI":"10.1016\/j.ijid.2022.03.026"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2340\/00015555-2577","article-title":"Molecular characteristics of mycobacterium tuberculosis strains isolated from cutaneous tuberculosis patients in China","volume":"97","author":"Jiang","year":"2017","journal-title":"Acta Derm.-Venereol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/lungindia.lungindia_192_18","article-title":"Extrapulmonary drug-resistant tu.uberculosis at a drug-resistant tuberculosis center, Mumbai: Our experience\u2013Hope in the midst of despair!","volume":"36","author":"Desai","year":"2019","journal-title":"Lung India"},{"key":"ref_54","first-page":"38","article-title":"Idiopathic granulomatous mastitis","volume":"103","author":"Haitz","year":"2019","journal-title":"Cutis"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Sener, A., and Erdem, H. (2019). Cutaneous Tuberculosis. Extrapulmonary Tuberculosis, Springer. [1st ed.].","DOI":"10.1007\/978-3-030-04744-3"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.med.2018.03.020","article-title":"Infecciones bacterianas cr\u00f3nicas (I). Tuberculosis","volume":"12","author":"Blasco","year":"2018","journal-title":"Med.-Programa de Form. M\u00e9dica Contin. Acreditado"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.mpmed.2017.09.008","article-title":"Extrapulmonary tuberculosis","volume":"45","author":"Peirse","year":"2017","journal-title":"Medicine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4103\/0971-5916.171284","article-title":"Drug resistance among extrapulmonary TB patients: Six years\u2019 experience from a supranational reference laboratory","volume":"142","author":"Dusthackeer","year":"2015","journal-title":"Indian J. Med. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4046\/trd.2015.78.2.47","article-title":"Diagnosis and treatment of extrapulmonary tuberculosis","volume":"78","author":"Lee","year":"2015","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1574-695X.2012.00987.x","article-title":"Diagnosis of extrapulmonary tuberculosis by PCR","volume":"66","author":"Mehta","year":"2012","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/0970-2113.83977","article-title":"Tuberculosis chemotherapy in the 21st century: Back to the basics","volume":"28","author":"Joshi","year":"2011","journal-title":"Lung India"},{"key":"ref_62","first-page":"5","article-title":"Medical schools and tuberculosis control: Bridging the discordance between what is preached and what is practiced","volume":"46","author":"Mohan","year":"2004","journal-title":"Indian J. Chest Dis. Allied Sci."},{"key":"ref_63","first-page":"19","article-title":"Cutaneous tuberculosis: A practical case report and review for the dermatologist","volume":"2","author":"Frankel","year":"2009","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1590\/abd1806-4841.20188560","article-title":"Scrofuloderma: A diagnostic challenge","volume":"94","author":"Baeta","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez, N.P. (2012). Cutaneous manifestations of pulmonary disease. Atlas of Dermatology in Internal Medicine, Springer. [14th ed.].","DOI":"10.1007\/978-1-4614-0688-4"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/0019-5154.123511","article-title":"Tuberculosis verrucosa cutis presenting as diffuse plantar keratoderma: An unusual sight","volume":"59","author":"Ghosh","year":"2014","journal-title":"Indian J. Dermatol."},{"key":"ref_67","unstructured":"Spiro, S.G., Silvestri, G.A., and Agust\u00ed, A. (2012). Tuberculosis and nontuberculous mycobacterial infections. Clinical Respiratory Medicine, Elsevier Ltd.. [4th ed.]."},{"key":"ref_68","unstructured":"Guerrant, R.L., Walker, D.H., and Weller, P.F. (2011). Tuberculosis and atypical mycobacterial infections. Tropical Infectious Diseases, Elsevier Inc.. [3rd ed.]."},{"key":"ref_69","first-page":"31.1","article-title":"Mycobacterial infections","volume":"Volume 2","author":"Burns","year":"2010","journal-title":"Rook\u2019s Textbook of Dermatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"bcr2012006253","DOI":"10.1136\/bcr-2012-006253","article-title":"Cutaneous tuberculosis caused by isoniazid-resistant Mycobacterium tuberculosis","volume":"2012","author":"Gharabaghi","year":"2012","journal-title":"BMJ Case Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3855\/jidc.2729","article-title":"Skin biopsy: A pillar in the identification of cutaneous Mycobacterium tuberculosis infection","volume":"6","author":"Cazarez","year":"2012","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/jdv.14851","article-title":"Cutaneous tuberculosis in China\u2014A multicentre retrospective study of cases diagnosed between 1957 and 2013","volume":"32","author":"Zhang","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_73","first-page":"272","article-title":"Cutaneous tuberculosis in Hong Kong: An update","volume":"12","author":"Ho","year":"2006","journal-title":"Hong Kong Med. J."},{"key":"ref_74","first-page":"193","article-title":"Clinical and morphological variants of cutaneous tuberculosis and its relation to Mycobacterium species","volume":"19","author":"Gopinathan","year":"2001","journal-title":"Indian J. Med. Microbl."},{"key":"ref_75","unstructured":"Kaul, S., Kaur, I., Mehta, S., and Singal, A. (2022). Cutaneous tuberculosis. Part I: Pathogenesis, classification, and clinical features. JAAD, (in press)."},{"key":"ref_76","first-page":"e005070","article-title":"Understanding cutaneous tuberculosis: Two clinical cases","volume":"3","author":"Trecarichi","year":"2016","journal-title":"JMM Case Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1590\/S1806-37132007000300015","article-title":"Immunological diagnosis of tuberculosis: Problems and strategies for success","volume":"33","author":"Teixeira","year":"2007","journal-title":"J. Bras. Pneumol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/trstmh\/trv107","article-title":"Management of multidrug-resistant TB: Novel treatments and their expansion to low resource settings","volume":"110","author":"Sloan","year":"2016","journal-title":"Trans. R Soc. Trop Med. Hyg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clindermatol.2019.01.008","article-title":"Cutaneous Tuberculosis: A Great Imitator","volume":"37","author":"Chen","year":"2019","journal-title":"Clin. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jaad.2019.05.025","article-title":"The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers","volume":"81","author":"Karas","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","first-page":"560","article-title":"Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh","volume":"8","author":"Salim","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/rccm.201710-2141OC","article-title":"Clinical management of multidrug-resistant tuberculosis in 16 European countries","volume":"198","author":"Alexandru","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/INF.0000000000002040","article-title":"Increasing Prevalence of Pediatric Drug-resistant Tuberculosis in Mumbai, India, and Its Outcome","volume":"37","author":"Shah","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S1473-3099(18)30104-X","article-title":"Precision medicine for drug-resistant tuberculosis in high-burden countries: Is individualised treatment desirable and feasible?","volume":"18","author":"Cox","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/1791013a0","article-title":"A new series of phenazines (rimino-compounds) with high antituberculosis activity","volume":"179","author":"Barry","year":"1957","journal-title":"Nature"},{"key":"ref_86","unstructured":"Drugbank (2021, June 03). Clofazimine. Available online: https:\/\/www.drugbank.ca\/drugs\/DB00845."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e00636-18","DOI":"10.1128\/AAC.00636-18","article-title":"Impact of clofazimine dosing on treatment-shortening of the first-line regimen in a mouse model of tuberculosis","volume":"62","author":"Ammerman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"ofx147","DOI":"10.1093\/ofid\/ofx147","article-title":"Clofazimine in nontuberculous mycobacterial infections: A growing niche","volume":"4","author":"McGuffin","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"Swanson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: Current status and future prospects","volume":"67","author":"Cholo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e02164-20","DOI":"10.1128\/AAC.02164-20","article-title":"Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models","volume":"11","author":"Zhu","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","first-page":"6","article-title":"\u201cB 663\u201d in the treatment of leprosy. Preliminary report of a pilot trial","volume":"33","author":"Browne","year":"1962","journal-title":"Lepr. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tips.2018.03.003","article-title":"Orphan drugs and their impact on pharmaceutical development","volume":"39","author":"Attwood","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_94","first-page":"85","article-title":"Tuberculosis","volume":"Volume 88","author":"Brennan","year":"2008","journal-title":"Handbook of Anti-Tuberculosis Agents"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkw426","article-title":"Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline","volume":"72","author":"Cholo","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijantimicag.2014.09.012","article-title":"In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates","volume":"45","author":"Zhang","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jis460","article-title":"Efficacy Subgroup, RESIST-TB. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: Unclear efficacy or untapped potential?","volume":"207","author":"Dooley","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.biopha.2018.06.023","article-title":"Clofazimine: A useful antibiotic for drug-resistant tuberculosis","volume":"105","author":"Mirnejad","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20189-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardized short-course multidrug-resistant tuberculosis treatment in Niger: No relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_102","first-page":"1361","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China","volume":"60","author":"Tang","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1073\/pnas.1416951112","article-title":"Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis","volume":"112","author":"Tyagi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","article-title":"Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice","volume":"188","author":"Grosset","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1016\/S2214-109X(19)30186-X","article-title":"Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis","volume":"7","author":"Seung","year":"2019","journal-title":"Lancet Glob Health"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.leukres.2017.01.019","article-title":"Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line","volume":"55","author":"Durusu","year":"2017","journal-title":"Leuk Res."},{"key":"ref_107","unstructured":"Food and Drug Administration (2022, January 05). LAMPRENE\u00ae (clofazimine) Capsules, Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019500s013lbl.pdf."},{"key":"ref_108","unstructured":"Novartis (2022, January 05). Lamprene\u00ae Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/19500slr010_lamprene_lbl.pdf."},{"key":"ref_109","first-page":"2628913","article-title":"Resistance to second-line antituberculosis drugs and delay in drug susceptibility testing among multidrug-resistant tuberculosis patients in Shanghai","volume":"2016","author":"Chen","year":"2016","journal-title":"BioMed. Res. Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1602445","DOI":"10.1183\/13993003.02445-2016","article-title":"Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: A nationwide report from Brazil","volume":"49","author":"Dalcolmo","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"ofw004","DOI":"10.1093\/ofid\/ofw004","article-title":"Clofazimine enteropathy: A rare and under recognized complication of mycobacterial therapy","volume":"2","author":"Szeto","year":"2016","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00265-16","article-title":"Clofazimine biocrystal accumulation in macrophages upregulates interleukin 1 receptor antagonist production to induce a systemic anti-inflammatory state","volume":"60","author":"Yoon","year":"2016","journal-title":"Antimicrobl. Agents Chemothe."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis","volume":"17","author":"Gopal","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4103\/0301-4738.82012","article-title":"Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosy patient","volume":"59","author":"Barot","year":"2011","journal-title":"Indian J. Ophthalmol."},{"key":"ref_115","first-page":"87","article-title":"Effect of clofazimine on eye in multibacillary leprosy","volume":"62","author":"Kaur","year":"1990","journal-title":"Indian J. Lepr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"38276","DOI":"10.18632\/oncotarget.11299","article-title":"Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma","volume":"8","author":"Zaccagnino","year":"2017","journal-title":"Oncotarget"},{"key":"ref_117","first-page":"476","article-title":"Clofazimine induced nail changes","volume":"61","author":"Dixit","year":"1989","journal-title":"Indian J. Lepr."},{"key":"ref_118","unstructured":"World Health Organization (1998). WHO Model Prescribing Information: Drugs Used in Leprosy, World Health Organization. Available online: http:\/\/apps.who.int\/medicinedocs\/pdf\/h2988e\/h2988e.pdf."},{"key":"ref_119","unstructured":"National Hansen\u2019s Disease (Leprosy) Program (2022, January 05). Recommended Treatment Regimens, Available online: https:\/\/www.hrsa.gov\/hansensdisease\/diagnosis\/recommendedtreatment.html."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e004143","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: Analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e12414","DOI":"10.1111\/dth.12414","article-title":"Leprosy treatment during pregnancy and breastfeeding: A case report and brief review of literature","volume":"30","author":"Ozturk","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1086\/430066","article-title":"Treatment of multidrug-resistant tuberculosis during pregnancy: Long-term follow-up of 6 children with intrauterine exposure to second-line agents","volume":"40","author":"Drobac","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/infdis\/jix083","article-title":"Clofazimine Mechanisms of Action in Mycobacteria, HIV, and Cancer","volume":"215","author":"Levis","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejps.2018.07.038","article-title":"Cocrystallization as a novel approach to enhance the transdermal administration of meloxicam","volume":"123","author":"Machado","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1517\/13543776.2016.1131267","article-title":"Topical drug delivery systems: A patent review","volume":"26","author":"Mital","year":"2016","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_126","first-page":"12","article-title":"Recent advances in novel topical drug delivery system","volume":"1","author":"Bhowmik","year":"2012","journal-title":"Pharm. Innov."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ejps.2013.03.019","article-title":"Next generation intra-and transdermal therapeutic systems: Using non-and minimally-invasive technologies to increase drug delivery into and across the skin","volume":"50","author":"Gratieri","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd1304","article-title":"Current status and future potential of transdermal drug delivery","volume":"3","author":"Prausnitz","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/10717544.2018.1559258","article-title":"Design, characterization and comparison of transdermal delivery of colchicine via borneol-chemically-modified and borneol-physically-modified ethosome","volume":"26","author":"Zhang","year":"2019","journal-title":"Drug Deliv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejps.2018.08.025","article-title":"Investigation of the enhancement effect of the natural transdermal permeation enhancers from Ledum palustre L. var. angustum N. Busch: Mechanistic insight based on interaction among drug, enhancers and skin","volume":"124","author":"Nan","year":"2018","journal-title":"Eur. J. Pharm Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/pharmaceutics7030090","article-title":"Transdermal delivery of drugs with microneedles\u2014potential and challenges","volume":"7","author":"Ita","year":"2015","journal-title":"Pharmaceutics"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2016.12.022","article-title":"Topical and cutaneous delivery using nanosystems","volume":"247","author":"Roberts","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.steroids.2015.04.006","article-title":"On the role of skin in the regulation of local and systemic steroidogenic activities","volume":"103","author":"Slominski","year":"2015","journal-title":"Steroids"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejpb.2019.02.012","article-title":"Lipid gene nanocarriers for the treatment of skin diseases: Current state-of-the-art","volume":"137","author":"Bellefroid","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/10717544.2014.935532","article-title":"Permeation enhancer strategies in transdermal drug delivery","volume":"23","author":"Marwah","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijpharm.2015.10.034","article-title":"Optimised transdermal delivery of pravastatin","volume":"496","author":"Burger","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5","DOI":"10.22159\/ajpcr.2017.v10i9.19389","article-title":"Natural permeation enhancer for transdermal drug delivery system and permeation evaluation: A review","volume":"10","author":"Das","year":"2017","journal-title":"Asian J. Pharm. Cli. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pharep.2016.10.011","article-title":"The application of skin metabolomics in the context of transdermal drug delivery","volume":"69","author":"Li","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/ten.tec.2014.0065","article-title":"Lowered humidity produces human epidermal equivalents with enhanced barrier properties","volume":"21","author":"Sun","year":"2014","journal-title":"Tissue Eng. Part. C Methods"},{"key":"ref_140","first-page":"10","article-title":"Drug penetration enhancement in transdermal drug delivery system by chemical penetration enhancers","volume":"4","author":"Ramani","year":"2013","journal-title":"Int. J. Preclin. Pharm. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1461-5347(00)00295-9","article-title":"Transdermal drug delivery: Overcoming the skin\u2019s barrier function","volume":"3","author":"Naik","year":"2000","journal-title":"Pharm. Sci. Technolo. Today"},{"key":"ref_142","unstructured":"British Pharmacopoeia (BP) (2022, March 22). Clofazomine. Available online: https:\/\/www-pharmacopoeia-com.nwulib.nwu.ac.za\/bp-2018\/monographs\/clofazimine.html?date=2018-01-01&page=21."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/pharmaceutics7040438","article-title":"Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum","volume":"7","author":"Alkilani","year":"2015","journal-title":"Pharmaceutic"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"38214","DOI":"10.18632\/oncotarget.17130","article-title":"Size-dependent penetration of nanoemulsions into epidermis and hair follicles: Implications for transdermal delivery and immunization","volume":"8","author":"Su","year":"2017","journal-title":"Oncotarget"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eplepsyres.2016.10.020","article-title":"The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate","volume":"129","author":"Gidal","year":"2017","journal-title":"Epilepsy Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ajps.2017.07.004","article-title":"Film forming systems for topical and transdermal drug delivery","volume":"12","author":"Kathe","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1023\/A:1010948630296","article-title":"Supersaturation: Enhancement of skin penetration and permeation of a lipophilic drug","volume":"18","author":"Moser","year":"2001","journal-title":"Pharm. Res."},{"key":"ref_148","first-page":"357","article-title":"Melting point distribution analysis of globally approved and discontinued drugs: A research for improving the chance of success of drug design and discovery","volume":"5","author":"Mao","year":"2016","journal-title":"Chem. Open"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/10717540500395064","article-title":"Effect of different terpene-containing essential oils on percutaneous absorption of trazodone hydrochloride through mouse epidermis","volume":"13","author":"Das","year":"2006","journal-title":"Drug Deliv."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1124\/dmd.117.077834","article-title":"Evaluation of clinical drug interaction potential of clofazimine using static and dynamic modelling approaches","volume":"46","author":"Sangana","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1021\/acs.molpharmaceut.7b00521","article-title":"Design and solidification of fast-releasing clofazimine nanoparticles for treatment of cryptosporidiosis","volume":"14","author":"Zhang","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"20780","DOI":"10.3390\/molecules191220780","article-title":"Prodrug strategies for enhancing the percutaneous absorption of drugs","volume":"19","year":"2014","journal-title":"Molecules"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000094670","article-title":"The pH of the skin surface and its impact on the barrier function","volume":"19","author":"Korting","year":"2006","journal-title":"Skin Pharmacol. Physiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1590\/S1984-82502013000300004","article-title":"Basic considerations in the dermatokinetics of topical formulations","volume":"49","author":"Nair","year":"2013","journal-title":"Braz. J. Pharm. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3797\/scipharm.1108-20","article-title":"Iontophoresis: A Potential Emergence of a Transdermal Drug Delivery System","volume":"8","author":"Dhote","year":"2012","journal-title":"Sci. Pharm."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/21691401.2018.1430695","article-title":"Passive delivery of protein drugs through transdermal route","volume":"46","author":"Chaulagain","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_157","first-page":"e00070","article-title":"Effect of pH on weakly acidic and basic model drugs and determination of their ex vivo transdermal permeation routes","volume":"54","author":"Pranitha","year":"2018","journal-title":"Braz. J. Pharm. Sci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3109\/03639045.2015.1047847","article-title":"Penetration enhancing effects of selected natural oils utilized in topical dosage forms","volume":"41","author":"Viljoen","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"\u010ci\u017einauskas, V., Elie, N., Brunelle, A., and Briedis, V. (2017). Skin Penetration Enhancement by Natural Oils for Dihydroquercetin Delivery. Molecules, 22.","DOI":"10.3390\/molecules22091536"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12906-017-1858-1","article-title":"Ethnopharmacological survey of home remedies used for treatment of hair and scalp and their methods of preparation in the West Bank-Palestine","volume":"17","author":"Zaid","year":"2017","journal-title":"BMC Complement. Altern Med."},{"key":"ref_161","unstructured":"(2015). Standard for Olive Oils and Olive Pomace Oils CODEX STAN 33\u20131981. International Food Standards: World Health Organization Food and Agriculture Organization of the United Nations, WHO. Available online: https:\/\/www.fao.org\/fao-who-codexalimentarius\/sh-proxy\/en\/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXS%2B33-1981%252FCXS_033e.pdf."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Lin, T.K., Zhong, L., and Santiago, J. (2018). Anti-inflammatory and skin barrier repair effects of topical application of some plant oils. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010070"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40257-017-0301-1","article-title":"Natural oils for skin-barrier repair: Ancient compounds now backed by modern science","volume":"19","author":"Vaughn","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"354","DOI":"10.12968\/bjom.2011.19.6.354","article-title":"A national survey of UK maternity and neonatal units regarding the use of oil for baby skincare","volume":"19","author":"Cooke","year":"2011","journal-title":"Br. J. Midwifery"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s13312-010-0114-2","article-title":"Massage and touch therapy in neonates: The current evidence","volume":"47","author":"Kulkarni","year":"2010","journal-title":"Indian Pediatr."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2165\/00128071-200304110-00005","article-title":"Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders","volume":"4","author":"Loden","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.3390\/molecules161210507","article-title":"Transdermal drug delivery enhancement by compounds of natural origin","volume":"16","author":"Fox","year":"2011","journal-title":"Molecules"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1800431","DOI":"10.1002\/ejlt.201800431","article-title":"A novel aqueous extraction for camellia oil by emulsified oil: A frozen\/thawed method","volume":"121","author":"Yang","year":"2019","journal-title":"Eur. J. Lipid Sci. Tech."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"20120788","DOI":"10.1098\/rsif.2012.0788","article-title":"Controlling the hydration of the skin though the application of occluding barrier creams","volume":"10","author":"Sparr","year":"2013","journal-title":"J. Royal Soc. Interface"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Carranco, N., Farr\u00e9s-Cebri\u00e1, M., Saurina, J., and N\u00fa\u00f1ez, O. (2018). Authentication and quantitation of fraud in extra virgin olive oils based on HPLC-UV fingerprinting and multivariate calibration. Foods, 7.","DOI":"10.3390\/foods7040044"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3329\/dujps.v10i1.10018","article-title":"Comparative study of ibuprofen solubility in synthetic and natural lipid vehicles","volume":"10","author":"Roni","year":"2011","journal-title":"Dhaka Univ. J. Pharml. Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"111748","DOI":"10.1016\/j.colsurfb.2021.111748","article-title":"Skin penetration\/permeation success determinants of nanocarriers: Pursuit of a perfect formulation","volume":"203","author":"Elmowafy","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03639045.2012.660949","article-title":"Role of excipients in successful development of self-emulsifying\/microemulsifying drug delivery system (SEDDS\/SMEDDS)","volume":"39","author":"Rahman","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jconrel.2017.12.027","article-title":"Do drug release studies from SEDDS make any sense?","volume":"271","author":"Jalil","year":"2018","journal-title":"J. Control. Releas"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejpb.2017.04.021","article-title":"Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery","volume":"117","author":"Morgen","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.tips.2008.08.001","article-title":"Rising standards for tuberculosis drug development","volume":"29","author":"Balganesh","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1080\/10717544.2016.1214990","article-title":"Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view","volume":"23","author":"Chatterjee","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.colsurfa.2017.10.076","article-title":"Production, properties, and applications of solid self-emulsifying delivery systems (S-SEDS) in the food and pharmaceutical industries","volume":"538","author":"Nikmaram","year":"2018","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1248\/cpb.c18-00868","article-title":"A simple and easy method of monitoring doxorubicin release from a liposomal drug formulation in the serum using fluorescence spectroscopy","volume":"67","author":"Watanabe","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Gupta, P.K., Bhandari, N., Shah, H.N., Khanchandani, V., Keerthana, R., Nagarajan, V., and Hiremath, L. (2019). An update on nanoemulsions using nanosized liquid in liquid colloidal systems. Nanoemulsions\u2014Properties, Fabrications and Applications, IntechOpen. Online First.","DOI":"10.5772\/intechopen.84442"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Chime, S.A., Kenechukwu, F.C., and Attama, A.A. (2014). Nanoemulsions\u2014Advances in formulation, characterization and applications in drug delivery. Application of Nanotechnology in Drug Delivery, IntechOpen.","DOI":"10.5772\/58673"},{"key":"ref_182","unstructured":"Aulton, M.E., and Taylor, K.M.G. (2018). Topical and transdermal drug delivery. Aulton\u2019s Pharmaceutics: The Design and Manufacture of Medicines, Churchill Livingstone. [5th ed.]."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0928-0987(01)00167-1","article-title":"Novel mechanisms and devices to enable successful transdermal drug delivery","volume":"14","author":"Barry","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0378-5173(99)00441-X","article-title":"Oestradiol skin delivery from ultradeformable liposomes: Refinement of surfactant concentration","volume":"196","author":"Williams","year":"2000","journal-title":"Int. J. Pharm."},{"key":"ref_185","first-page":"843","article-title":"Development of surfactant free nanoparticles by a single emulsion high pressure homogenization technique and effect of formulation parameters on the drug entrapment and release","volume":"3","author":"Patil","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jddst.2018.01.013","article-title":"Design and evaluation of SEDDS exhibiting high emulsifying properties","volume":"44","author":"Rohrer","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejpb.2017.03.012","article-title":"Self-emulsifying drug delivery systems: Design of a novel vaginal delivery system for curcumin","volume":"115","author":"Nardin","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.5530\/ijper.50.3.29","article-title":"A new self microemulsifying mouth dissolving film","volume":"50","author":"Pattewar","year":"2016","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijpharm.2013.10.044","article-title":"Ocular supersaturated self-nanoemulsifying drug delivery systems (S-SNEDDS) to enhance econazole nitrate bioavailability","volume":"460","author":"ElKasabgy","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3109\/03639045.2012.723716","article-title":"A new self-microemulsifying mouth dissolving film to improve the oral bioavailability of poorly watersoluble drugs","volume":"39","author":"Xiao","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2174\/1568026618666181025104818","article-title":"Formulation and characterization of a self-emulsifying drug delivery system (sedds) of curcumin for the topical application in cutaneous and mucocutaneous leishmaniasis","volume":"18","author":"Khan","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5530\/jyp.2017.9.68","article-title":"Self-nanoemulsifying drug delivery system (Snedds) for topical delivery of mangosteen peels (Garcinia mangostana L.): Formulation Design and In vitro Studies","volume":"9","author":"Pratiwi","year":"2017","journal-title":"J. Young Pharm."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2017.11.003","article-title":"Measuring the emulsification dynamics and stability of self-emulsifying drug delivery systems","volume":"123","author":"Vasconcelos","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1208\/s12249-019-1335-x","article-title":"Self-emulsifying oral lipid drug delivery systems: Advances and challenges","volume":"20","author":"Rani","year":"2019","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Nikolakakis, I., and Partheniadis, I. (2017). Self-emulsifying granules and pellets: Composition and formation mechanisms for instant or controlled release. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9040050"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4103\/0250-474X.159596","article-title":"Role of components in the formation of self-microemulsifying drug delivery systems","volume":"77","author":"Gurram","year":"2015","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_197","unstructured":"Kemppainen, B.W., and Reifenrath, W.G. (1990). Penetrant characteristics influencing skin absorption. Methods for Skin Absorption, CRC Press. [1st ed.]."},{"key":"ref_198","first-page":"3114","article-title":"Self-emulsifying drug delivery system (SEDDS): A conventional alternative and approach to improve oral bioavailability","volume":"9","author":"Rajeshwar","year":"2018","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/10717544.2013.861659","article-title":"Self-emulsifying drug delivery system and the applications in herbal drugs","volume":"22","author":"Zhang","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s11095-010-0309-1","article-title":"Nano-emulsions and micro-emulsions: Clarifications of the critical differences","volume":"28","author":"Anton","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_201","first-page":"140","article-title":"A review on self-emulsified drug delivery system","volume":"3","author":"Thakare","year":"2016","journal-title":"Pharm. Biol. Eval."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biopha.2016.02.039","article-title":"Mixed surfactant based (SNEDDS) self-nanoemulsifying drug delivery system presenting efavirenz for enhancement of oral bioavailability","volume":"80","author":"Senapati","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.colsurfa.2015.11.017","article-title":"Non-aqueous self-double-emulsifying drug delivery system: A new approach to enhance resveratrol solubility for effective transdermal delivery","volume":"489","author":"Hu","year":"2016","journal-title":"Colloids Surf. A Physicochem."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"van Staden, D., du Plessis, J., and Viljoen, J. (2020). Development of topical\/transdermal self-emulsifying drug delivery systems, not as simple as expected. Sci. Pharm., 88.","DOI":"10.3390\/scipharm88020017"},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"van Staden, D., du Plessis, J., and Viljoen, J. (2020). Development of a self-emulsifying drug delivery system for optimized topical delivery of clofazimine. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060523"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2018.04.004","article-title":"Lipid nanocarriers loaded with natural compounds: Potential new therapies for age related neurodegenerative diseases?","volume":"168","author":"Soares","year":"2018","journal-title":"Prog. Neurobiol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"121656","DOI":"10.1016\/j.ijpharm.2022.121656","article-title":"Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis","volume":"618","author":"Gama","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_208","first-page":"964051","article-title":"Self-microemulsifying drug delivery systems: An attractive strategy for enhanced therapeutic profile","volume":"2014","author":"Akula","year":"2014","journal-title":"Int. Sch. Res. Notices"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.addr.2012.04.003","article-title":"Modelling the human skin barrier\u2014Towards a better understanding of dermal absorption","volume":"65","author":"Jepps","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1211\/0022357021918","article-title":"Evidence for lymphatic transport of insulin by topically applied biphasic vesicles","volume":"55","author":"King","year":"2003","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijpharm.2018.02.019","article-title":"Mucoadhesive self-emulsifying delivery systems for ocular administration of econazole","volume":"541","author":"Elbahwy","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijpharm.2017.01.012","article-title":"Improved mucoadhesive properties of self-nanoemulsifying drug delivery systems (SNEDDS) by introducing acyl chitosan","volume":"519","author":"Efiana","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejpb.2016.11.019","article-title":"Self-emulsifying drug delivery systems (SEDDS): Proof-of-concept how to make them mucoadhesive","volume":"112","author":"Leonaviciute","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijpharm.2018.08.046","article-title":"Self-emulsifying drug delivery systems changing their zeta potential via a flip-flop mechanism","volume":"550","author":"Salimi","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.addr.2017.10.004","article-title":"Enzyme decorated drug carriers: Targeted swords to cleave and overcome the mucus barrier","volume":"124","author":"Menzel","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12941-017-0239-4","article-title":"Treating tuberculosis with high doses of anti-TB drugs: Mechanisms and outcomes","volume":"16","author":"Xu","year":"2017","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4155\/tde-2016-0092","article-title":"Antimalarial solid self-emulsifying system for oral use: In vitro investigation","volume":"8","author":"Bhandari","year":"2017","journal-title":"Ther. Deliv."},{"key":"ref_218","first-page":"42","article-title":"Self-emulsifying drug delivery system (SEDDS): A review","volume":"2","author":"Nigade","year":"2012","journal-title":"Int. J. Pharm. Biol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4103\/ijp.IJP_574_16","article-title":"Antibiotic resistance: Alternative approaches","volume":"49","author":"Gaur","year":"2017","journal-title":"Indian J. Pharmacol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jgar.2022.03.008","article-title":"Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro","volume":"29","author":"Mashele","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e00434-21","DOI":"10.1128\/Spectrum.00434-21","article-title":"Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy","volume":"9","author":"Tanner","year":"2021","journal-title":"Microbiol. Spectr."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/806\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:32:06Z","timestamp":1760139126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/6\/806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":221,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["antibiotics11060806"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11060806","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}